Björn Borg (“Björn Borg”, “the Company” or “the Group”) is a well-established and renowned company w...
Redeye comments on the outcome of Iconovo’s rights issue.
Obducat AB (publ) (”Obducat” eller ”Bolaget”) levererade stark exekvering under det tredje kvartalet...
Medical cannabis has been legal in Denmark under a pilot program since 2018 during a trial period th...
Q3: 18% ARR growth vs. ABGSCe 19.5%, FCF slightly lower '24 guidance modified yesterday - lower ARR,...
Q3 EBIT -94m (ABGSCe SEK -19m) Minor estimate revisions, given Q3 small quarter Fågelås, Boarp, Dåll...
Redeye comments on Asmodee’s CMD which focused on the tabletop market dynamics, the company’s busine...
Redeye updates its fair value range following Friday’s Q3 report and after the outcome of the extra ...
We cut '24e-'26e adj. EBITDA by 13-9% Shareholders accept the large divestment '25e EV/EBITA ~5x Wh...
FY'24 ARR guidance lowered to DKK 101m-106m on KYC delays.
Redeye views Xbrane’s announcement of a partner for its Opdivo biosimilar as a positive development ...
Den 6:e november kommenterade Analysguiden iZafes rapport för det tredje kvartalet.
Mangold uppdaterar sin syn på greentech-bolaget ChargePanel efter det tredje kvartalet 2024.
Redeye comments on Active Biotech's 2024 rights issue and updates its base case.
Under kvartalet nåddes överenskommelser med majoriteten av obligationsinvesterarna och efter kvartal...
Underliggande verksamheter går fortsatt mycket bra, men viss mixförskjutning och förberedelsekostnad...
Redeye updates on Embracer following Q2-results which were lower than expected, owing mainly to soft...
Redeye downgrades Nekkar’s outlook on the back of a Q3’24 report that missed our forecast, mainly dr...
Redeye provides a short comment on the recently announced SEK12.
Redeye provides a brief comment on today’s news that Flexion Mobile has filed its 2023 annual accoun...
